15-JUL-2024 6:11

OPEN STUDIES IRB REPORT

Disease
Site		 Study Study Name Open Date Number of
Active
Institutions		 Number of
Current
IRBs
 
BREAST S2007 Breast, Brain Mets, Sacituzumab Govitecan 15-DEC-20 214 69
  S2206 Brst, Stg II-III, MP2, Neoadj Chemo +/- Durva 30-OCT-23 327 102
  S2212 Breast, TNBC, Neoadj Chemo + Pembro 21-JUL-23 306 122
  A011801 BRST, HER2+, T-DM1+Placebo v T-DM1+Tucatinib 06-JAN-21 426 202
  A012103 Breast,StgT1cN1-2/T2-4N0-2,obsvsPembrolizumab 03-MAY-23 353 166
  EA1211 Breast, HER2+, NeoAdj Therapy 10-MAY-23 1 3
  MA39 BREAST, Node-Pos, Reg RT vs No Reg RT 30-MAY-18 385 154
  NRGBR007 Breast, Stg I, De-Escalation of Breast RT 07-JUN-21 379 166
  NRGBR009 Breast, EarlyStg, Adjuvant Chemo 31-AUG-23 165 74
 
CCD S1703 Met Breast, STM-monitoring v Usual Care 16-JUL-18 224 91
  S1912CD CREDIT, Fin Counseling to reduce Fin Hardship 26-JUL-21 178 69
  S2108CD Genomic Tumor Board vs Usual Practice 22-AUG-22 24 29
  A191901 Brst, Text/Motivational Intervention ET Adher 10-DEC-20 187 89
  A231901C Breast, Shared Decision Engagement System 15-JAN-21 12 5
 
ERLYTX S2012 Small Cell NEC, Stg IV, Combo Chemo +/- Atezo 02-DEC-21 188 72
  A071401 Prog Meningiomas,SMO/AKT/NF2 Inhib 28-AUG-15 254 84
  AGCT1531 Mult, Stg I-IV, Carbo vs Cisp, Ped &Adult 08-MAY-17 188 117
  EAY191 ComboMATCH 06-MAR-23 265 111
  EAY191-S3 ComboMATCH: Adv Solid Tumors, Pac+Ipatasertib 06-MAR-23 181 62
  EAY191A3 ComboMATCH-RAS-Mutant, All Stg, Palbo+Benim 15-NOV-23 81 39
  EAY191E4 ComboMATCH-Pr. Tax-Tx Tumors, Pac+Nilotinib 07-JUN-23 136 59
 
GI S1922 Small Bowel,Ram+Pac vs FOLFIRI, mets/unresect 16-DEC-19 166 55
  S2001 Rando II, Mets Pancreas , BRCA1/2, Comb Chemo 04-DEC-20 176 72
  S2104 Panc,Resect High-risk,Postop Adj Chemo vs Obs 14-OCT-21 182 59
  S2107 Colorectal, BRAF mut, Enc + CET +/-Nivo 06-JUN-22 171 67
  S2303 Gas/Esoph/GEJ, Adv, Ram + Pac +/- Nivo 06-MAY-24 56 23
  A021806 Pancreas, Perioperative vs Adjuvant Chemo 01-JUL-20 269 121
  A022001 PANC, METS, Lu 177 Dotatate PRRT vs CAPTEM 16-MAR-22 59 27
  A022004 Colon, Stg II-III, Encor+Cetux vs SOC 30-MAY-23 15 9
  A022102 Gastric, FOLFIRINOX +/-Nivo vs FOLFOX +/ Nivo 11-JAN-23 233 92
  A022104 Rectal, Loc Adv, Triplet vs Doublet Chemo 09-NOV-22 344 132
  EA2174 Esoph, Peri-Op Nivolumab +/- Ipilimumab 17-JAN-19 235 91
  EA2176 Anal, Met, Immune Check Pt Inhibition + Chemo 15-OCT-20 220 89
  EA2182 Anal, Erly, DECREASE 12-NOV-19 301 97
  EA2192 Panc, APOLLO 29-APR-21 153 85
  EA2197 Gal, Rando Perioperative TX 22-DEC-20 134 69
  EA2222 Colorectal, Stg II-III, Hep Art Infusion 19-OCT-23 0 1
  NRGGI004 Colorectal, Stg IV, dMMR Immuno-Therapy 07-NOV-17 323 115
  NRGGI008 Colon, Stg III, Adj Chemo 10-MAR-22 424 174
 
GU S1802 Pros, Stg IV, SST +/- Surg/RT to Primary Tum 17-SEP-18 339 140
  S1931 RENAL, Stg IV, IO + Nephrectomy. vs IO Only 16-NOV-20 215 80
  S1937 Blad, Mets, Eribulin + Gem vs SOC 16-FEB-21 229 77
  S2200 pRCC, Adv, Cabo +/- Atezo 19-SEP-22 147 59
  S2210 Pros, High Risk, BRCA, Neoadj Carbo 14-AUG-23 126 38
  A021804 Adren, Advanced Stg, Temo w/wo Ola 02-NOV-20 0 1
  A031701 Bladder, ddGC for MIBC with DDR Tumor Alt 01-AUG-18 152 52
  A031702 GU, Mets, Cabozantinib+Nivo+Ipi (ICONIC) 12-APR-19 237 94
  A031801 GU, mRCC, Cabozantinib +/- Radium-223 13-DEC-19 87 38
  A031803 Blad, NMIBC, Gemcitabine + MK-3475 06-JAN-20 138 61
  A032103 Urothelial, All Stg, MRD-Based Adj Tx 09-JAN-24 155 54
  EA8134 Penile, Local Adv, ILND +/- Chemo or ChemoRT 08-SEP-17 37 16
  EA8171 PROS, newly diagnosed, mpMRI for pre-op stagi 09-JUL-18 96 48
  EA8191 Pros, Local vs Systemic Thrpy 08-OCT-20 198 65
  EA8192 Blad, High Grade UTUC, Durv + Chemo 06-MAY-21 153 55
  EA8212 Blad, NMIBC, BRIDGE 01-DEC-22 135 71
  NRGGU008 Pros,Node+, Abiraterone acetate + Apalutamide 05-MAR-20 234 84
  NRGGU009 Pros, PREDICT-RT 15-DEC-20 442 165
  NRGGU010 Pros, Parallel De-Intens & Intens Trials 03-NOV-21 442 161
  NRGGU011 Pros, Dbl Blinded RT +/- Androgen Dep Tx 08-DEC-21 206 75
  NRGGU012 Renal, Stg IV, Stereo Abl Rad Therapy 30-JUN-22 207 65
  NRGGU013 Prostate, High-Risk, Five Fraction Radiation 13-NOV-23 170 57
 
LEUK S1905 T-ALL/T-LBL, Rel/Ref, OBI-3424 17-AUG-20 60 25
  S1925 CLL/SLL, Newly Dx HR, Early vs Delayed V+O 14-DEC-20 248 98
  A041501 B-Cell ALL, Frontline Tx +/- Intuzumab Ozo 01-JUN-17 230 84
  A041701 AML, Age 60+, Conv Chemo +/- Uproleselan 16-JAN-19 166 60
  A041703 ALL, Newly Dx, Inotuzumab Ozogamicin + Blinat 16-NOV-18 136 54
  A042001 B-Cell ALL, Inotuzunab+chemo v Standard chemo 27-FEB-23 126 44
  EA9152 ALL, T/B-Cell, Venetoclax + Vincristine 26-APR-18 59 24
  EA9171 CML, Anti-PD-1 Pembrolizumab + TKIs 03-OCT-18 91 39
  EA9181 ALL, BCR-ABL+, Steroids+TKI+CT/Blinatumomab 14-OCT-20 176 59
  EA9213 T-ALL, dara-hyal for chemo refractory MRD 16-JUN-22 54 16
  MM1YA-S01 AML, High Risk, Age <60, 7+3 vs experimental 16-MAY-24 47 21
  MYELOMATCH MSRP for the NCI myeloMATCH Clinical Trials 16-MAY-24 86 37
 
LUNG S1827 SCLC, MRI Surveillance +/- PCI 10-JAN-20 338 129
  S1900E KRAS G12C: Sotorasib (AMG 510) 02-APR-21 320 127
  S1900G EGFR-Mut, MET-Amp: Capmat + Osimert +/- Ramu 03-APR-23 264 100
  S1900K MET Exon 14: Tepotinib +/- Ramucirumab 18-DEC-23 217 84
  S1914 NSCLC, High Risk Early Stg, SBRT +/- Atezo 25-MAR-20 362 131
  S1933 NSCLC, Stg II-III, RT + Atezo 15-JUN-20 117 43
  S2302 NSCLC, Stg IV or Recur, Ramu + Pembro vs SoC 06-MAR-23 472 192
  A081801 ALCHEMIST4, ALK and EGFR negative, Chemo-IO 03-JUN-20 413 173
  A082002 Lung, Adv, Systemic Tx +/- SBRT 21-DEC-21 207 64
  A151216 ALCHEMIST0 - screening 18-AUG-14 511 238
  EA5162 NSCLS,StgIV/IIB,EGFR exon20 insertion,AZD9291 05-APR-18 84 39
  EA5182 NSCLC, Met EGFR mut, AZD9291+Beva vs AZD9291 22-OCT-20 183 81
  LUNGMAP NSCLC, Adv, Master 28-JAN-19 424 178
  NRGLU008 Lung NSCL, StgII-III, StereoBodyRad/MedChemo 10-MAY-23 31 11
 
LYMPH S1608 FL, TGR-1202/Lenalidomide/CHOP or Benda +Ob 10-AUG-17 197 72
  S1918 DLBCL, Adv, Age 75+, CC-486 +/- R-miniCHOP 19-MAR-21 182 71
  S2114 NHL, Rel/Ref, CD19 CAR-T +/- Consolidation 23-FEB-23 125 40
  S2207 LBCL, Transplant Inelig, Targeted Tx + Tafa 30-JUN-23 96 33
  A051902 PTCL,CHO(E)PvCC-486-CHO(E)PvDuvelisib-CHO(E)P 30-JUL-21 168 71
  A052101 Lymph, Stg I-IV, Cont v Intermittent Zanub 08-SEP-23 199 72
  AHOD2131 cHL,StgI-II,StdTherapyvImmuno-oncologyTherapy 28-APR-23 200 109
  ANHL1931 PMBCL, Chemo-Immunotherapy +/- Nivo 07-JUN-21 225 107
  E4412 HD, RR, Ipilimumab +Nivo +Brentuximab Vedotin 24-JAN-14 98 56
  EA4151 Lymph, AHCT +/-Ritux, MRD Neg 29-AUG-17 232 81
 
MELAN S2015 MELAN, Stg I-II, 1cm v 2cm excision margins 08-APR-22 176 68
  A091903 Melan, Resected Mucosal, Adj Nivo +/- Cabo 01-JUN-22 94 53
  EA6141 Melan, Adv, Nivolumab+Ipi ± Sargmostim 10-SEP-15 251 95
  EA6192 Melan, Adv, Erly Discont of Antibdy Thrpy 27-AUG-20 129 51
  EA6194 Melan, Stage IIIB-D, Pembro +/- CMP-001 19-MAR-21 1 4
 
MMYEL S1803 MM, Maintenance, Len vs Len/Dara 27-JUN-19 322 127
  S2209 MM, Newly Dx, VRd-R->R v DRd-R->R v DRD-DR->D 30-MAY-23 183 70
  S2213 AL Amyloidosis, Newly Dx, Dara-VCD v ASCT 01-DEC-23 79 27
  EAA173 MYEL, SMM, Rd +/- Daratumumab 30-APR-19 236 98
  EAA181 Myel, Newly Dx, DRd=>DRd+/-Btz=>DR (EQUATE) 27-OCT-20 206 81
 
MULT S2101 Melan or HNSCC, Adv, Cabo + Nivo 14-OCT-22 144 59
 
OTHER A071701 BRAIN, Met, Geno-guided trial 15-AUG-19 220 73
  A071702 BRAIN, Blockade Tx in Recurrent Glioblastoma 30-OCT-20 135 61
  A092104 Uter,Adv, Olaparib+Temozolomide vs Inv Choice 09-DEC-22 165 60
  A092107 DDLPS. Palbocicli v Palbociclib+Cemiplimab 24-MAR-23 44 13
  A151804 irAEs, National Biorepository to Adv Studies 31-JAN-20 145 72
  ARST2031 RMS, Stg IV, VINO-AC+VINO-CPO vs VAC+VINO-CPO 13-SEP-21 191 94
  CCTGHN11 HN, All Stg, Guided Elec Contra Neck Tx 29-SEP-22 58 18
  EA3132 HN SCC, Stg III-IV , Adj RT +/- Cisp 29-MAR-16 222 70
  EA3161 HNC, HPV+ OPCA, (cisplatin+RT) +/- Nivo 20-JUN-19 244 95
  EA3191 HN, High Risk HNSCC, Adj +/- Pembro 08-JAN-21 198 70
  NRGBN003 Mening, Grd II, Observation vs Irradiation 14-JUN-17 263 90
  NRGBN011 Brain, Lomustine + Temo vs Temo 29-NOV-21 274 103
  NRGBN012 Brain, Pre- vs Post-Op Stereotactic Radiosurg 31-AUG-22 228 91
  NRGGY019 Ovar, Stg II-IV, Pac/Carb/Let vs. Let Mono 26-AUG-19 65 20
  NRGGY022 Mult Site/Stg, Carboplat Clearance Predict 18-NOV-19 0 1
  NRGGY026 Endomet, Stage I-IV, Pac/Car w/ HER HYL/PHE 12-AUG-22 23 10
  NRGHN005 HN, early stg P16-pos, randomize de-intensifi 10-JUL-19 388 126
  NRGHN006 HN, Erly Stg, Biopsy vs Dissection 08-JUL-20 214 72
  NRGHN009 HN, RT + HD Cisp vs RT + LD Cisp for SCCHN 27-OCT-21 260 105
  NRGHN010 HER2+ SGC, T-DM1 vs TH 30-SEP-22 158 47
  R1216 HN, Adv,Cis vs Dtx vs Dtx+Cetux 18-MAR-13 352 115
 
PREV A211801 Breast, Preventive, Denosumab 23-FEB-22 43 28
  A212102 Blind Ref Set for Multicancer Early Detection 01-AUG-22 193 91
  EA1151 Prev, Tomosynthesis Mammographic Screening 06-JUL-17 243 95
  EA2185 Panc, Impact of Panc Cyst Surveillance 16-JAN-20 133 74
  EA8184 Pros, Dbl Blind GTC vs Placebo 20-MAY-21 78 38
  NRGCC005 Colon,Non-AdvancedAdenomas,Colonoscopy5v10yrs 06-OCT-21 155 58
  NRGCC008 Ovar, BRCA1, non-inferiority of BLS vs BSO 23-JUN-20 328 136
 
SURV A211901 Cancer survivors who smoke, txt cessation 01-DEC-21 121 48
 
SXQOL S2010 ASPEN: Brst, Stg I-III, ASM vs Pt Ed 17-JAN-23 233 112
  S2205 ICE COMPRESS: Reduction of CIPN from Taxanes 16-MAR-23 14 30
  A222004 Mult, Olanza vs Megestrol for Anorexia 15-OCT-21 0 58
  ACCL1931 Leuk, All Stg, Levocarnitine Prophylaxis 14-AUG-23 139 60
  EAQ202 Improving AYA PROs in EA Trials 28-OCT-21 34 22
  NRGCC010 Endo, Stg I, LN Map for LE Limb Dysfunction 19-SEP-22 75 23
  NRGCC011 Breast, Survivors, Cog Training 02-FEB-24 67 31